BRCA loss of function including BRCA1 DNA-methylation, but not BRCA-unrelated homologous recombination deficiency, is associated with platinum hypersensitivity in high-grade ovarian cancer

Table 1 Associations of BRCA DNA-methylation and clinicopathological and genetic features

Variable			BRCA-methylation^§			BRCA-LOF by epigenetic or genetic aberrations
Variable		Total	No	Yes	P value	No	Yes	P value
Age	≤ 59.8 years	66	57	9	0.271	21	45	0.007
Age	> 59.8 years	65	60	5		36	29
FIGO stage	I/II	15	14	1	0.592	5	10	0.398
FIGO stage	III/IV	116	103	13		52	64
Tumor grade	2	54	50	4	0,309	25	29	0.590
Tumor grade	3	77	67	10		32	45
Residual disease	Macroscopically tumor-free or < 1 cm	91	83	8	0.244	44	47	0.080
	Any tumor residual (> 1 cm)	38	32	6		12	26
	n.a	2	–	–		–	–
Histology	HGSOC	114	102	12	0.877	50	64	0.835
Histology	HGEOC	17	15	2		7	10
BRCA genetic aberrations	Wild-type	70	57	13	0.002	57	13	< 0.001
BRCA genetic aberrations	Mutation (BRCA1; BRCA2)	61 (45; 16)	60 (45; 15)	1 (0; 1)		0	61 (45;16)
HRD	Low (< 1.77)	44	42	2	0.092	41	3	< 0.001
HRD	High (> 1.77)	76	65	11		15	61

The significance level (P) was determined by Chi Square analysis
Bold values indicate P-values < 0.05; the numbers in italics represent the specific data for BRCA1 and BRCA2 mutations
^§BRCA1 DNA methylation; BRCA2 DNA methylation was not detected
FIGO International Federation of Gynecology and Obstetrics; HGEOC high-grade endometrioid ovarian cancer; HGSOC high-grade serous ovarian cancer; HRD homologous recombination deficiency; LOF loss of function; n.a. not available

ISSN: 1868-7083